个人简历

近年来，以（共同）第一或者通信作者发表SCI论文20篇，包括Nat Commun (IF:12.12)、Leukemia (IF:12.01)、J Pineal Res (IF:10.39)、Cancer Res (IF: 9.12)、Clin Cancer Res (IF: 9.61)、Theranostics (3篇, IF:8.85)、Oncogene (IF: 7.59) 等国际知名期刊，累计影响因子超过150。这些成果主要阐明了肿瘤糖酵解、氧化还原代谢异常以及肿瘤转移和化疗耐药的调控机制，并发现了以代谢为靶点的新型化合物；在转化医学研究方面，开发了两个新型的Hsp90抑制剂及基于纳米材料的基因治疗新方法，并拓展了一些临床药物（甲磺酸萘莫司、哌克昔林、褪黑素、维生素C）的抗肿瘤用途，共申请国家发明专利7项，获得授权2项。近年的研究成果，对于阐明消化系统肿瘤发生发展的病因、复发转移、代谢异常和化疗耐药的调控机制，进行疾病的诊断和干预具有重要理论意义和潜在的临床应用价值。

研究领域

""主要致力于研究胃肠肿瘤代谢及免疫微环境重塑的调控机制及诊疗策略.""""

近期论文

1.H.Q. Ju, H. Ying, T. Tian, J. Ling, J. Fu, M. Wu, Y. Lu, Z. Zhuang, L. Yang, A. Achreja, G. Chen, D. Nagrath, M.C. Hung, R.A. DePinho, P. Huang*, R.H. Xu*, P.J. Chiao* Mutant Kras- and p16-Regulated NOX4 Activation Overcomes Metabolic Checkpoints in Development of Pancreatic Ductal Adenocarcinoma, Nature Communications, (2017) Feb 24;8:14437. (IF：12.12) 2.H.Q. Ju#, G. Zhan#, A. Huang, Y. Sun, S. Wen, J. Yang, W.H. Lu, R.H. Xu, J. Li, Y. Li, G.G. Manero, P. Huang*, Y. Hu*, ITD Mutation in FLT3 Tyrosine Kinase Promotes Warburg Effect and Renders Therapeutic Sensitivity to Glycolytic Inhibition, Leukimia 31(10) (2017) 2143-50. (IF：11.70) 3.H.Q. Ju#, H. Li#, T. Tian#, Y.X. Lu, L. Bai, L.Z. Chen, H. Sheng, H.Y. Mo, J.B. Zeng, W. Deng, P.J. Chiao, R.H. Xu*, Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation, J Pineal Res 60(1) (2016) 27-38. (IF：10.39) 4.Z. Zhuang #, H.Q. Ju #, M. Aguilar, T. Gocho, H. Li, T. Iida, H. Lee, X. Fan, H. Zhou, J. Ling, Z. Li, J. Fu, M. Wu, M. Li, D. Melisi, Y. Iwakura, K. Xu, J.B. Fleming, P.J. Chiao*, IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-kappaB Activation, Clin Cancer Res 22(6) (2016) 1432-44. (Co-first author, IF：9.62) 5.H.Q. Ju#, Y.X. Lu#, D.L. Chen#, T. Tian, H.Y. Mo, X.L. Wei, J.W. Liao, F. Wang, Z.L. Zeng, H. Pelicano, M. Aguilar, W.H. Jia, R.H. Xu*, Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications, Theranostics 6(8) (2016) 1160-75. (IF：8.71) 6.D.L. Chen#, Y.X. Lu#, J.X. Zhang, X.L. Wei, F. Wang, Z.L. Zeng, Z.Z. Pan, Y.F. Yuan, F.H. Wang, H. Pelicano, P.J. Chiao, P. Huang, D. Xie, Y.H. Li, H.Q. Ju*, R.H. Xu*, Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression, Theranostics 6(8) (2017) 4836-49. (Co-corresponding, IF：8.71) 7.Y.X. Lu, Q.N. Wu, D.L Chen, L.Z. Chen, Z.X. Wang, C. Ren, H.Y Mo, Y. Chen, H.Sheng, Y.N. Wang, Y.Wang, J.H. Lu, D.S. Wang, Z.L. Zeng, F.Wang, F.H. Wang, Y.H. Li, H.Q. Ju*, R.H. Xu*, Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation, Theranostics (2017), In press, (Co-corresponding, IF：8.71) 8.H.Q. Ju#, Y.X. Lu#, Q.N. Wu#, J. Liu, Z.L. Zeng, H.Y. Mo, Y. Chen, Y. Wang, H.Y. Pu, F. Wang, T.B. Kang, D. Xie, M.S. Zeng, P. Huang*, R.H. Xu*, Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer, Oncogene 36(45) (2017) 6282-6292. (7.52) 9.H.Q. Ju#, Z.N. Zhuang#, H. Li#, T. Tian, Y.X. Lu, X.Q. Fan, H.J. Zhou, H.Y. Mo, H. Sheng, P.J. Chiao, R.H. Xu*, Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer, Cancer Lett 379(1) (2016) 1-11. (IF：6.38) 10.H.Q. Ju#, T. Gocho#, M. Aguilar, M. Wu, Yanaga, P. Huang, P., J. Chiao*, Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation, Mol Cancer Ther 14(3) (2015) 788-98. (IF：5.76)